Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insu...

Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune conditions, offering ...

NTPC along with its arm NTPC Green Energy signed multiple MoUs with Madhya Pradesh government to invest over Rs 2 lakh crore in the state.

Shares of Nestle India, IndusInd Bank, Sun Pharma, ONGC, Vedanta and Marico will be in focus as the companies will announce their third qua...

Biocon share price: This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concern...

The company is in discussions with banks for the issuance, the people said, asking not to be named because the details are private. Funds f...

Domestic markets rally on exit polls predicting Modi government's massive mandate. ZEE, M&M Financial, Dr Reddy's, Wipro, Biocon in focus. ...

Biocon Biologics has announced that its insulin manufacturing facility in Johor, Malaysia has been classified as an official action indicat...

Dr Reddy's Laboratories (DRL) and Intas Pharmaceuticals, both Indian companies, are reportedly in the race to acquire the biosimilar produc...

The special CBI court, in an 80-page order rejecting the bail pleas of all five accused in the case earlier this week, said: "The questions...

The CBI last month arrested Central Drugs Standard Control Organisation (CDSCO) joint drug controller S Eswara Reddy and Biocon Biologics h...

"And obviously, we expect the IPO to be at a very, very attractive level. So if you look at it, it's going to hugely create value for share...

“It adds to our armoury. I hope it is one more step towards vaccinating the general population,” Shaw told ET on hearing the news about a t...

Biocon's Executive Chairperson Kiran Mazumdar-Shaw on the company’s plans for fresh capital infusion in Biocon Biologics, growth opportunit...

Post the completion of this transaction, Biocon will hold a 95.25 per cent stake in Biocon Biologics.

Biosimilar drugs are identical copy of highly complex biologic drugs that claim to have the same efficacy as that off the innovator’s versi...

The total valuation of Syngene with this investment stands at Rs 1600 cr. Following the news, Biocon shares jumped by over 3%.